IBRX:NASDAQImmunityBio, Inc. Analysis

ImmunityBio (IBRX) trades around $7.20, just above its 20‑day SMA of $7.52 and the 50‑day SMA of $7.55, indicating a flat price action. Technical signals are mixed: the RSI sits at 45.7 (neutral), while the MACD shows a bearish divergence (line –0.176 vs signal –0.127). Volatility is extreme at 70% over the past 30 days and beta is near 2, underscoring high market sensitivity. Fundamentally, the stock is highly valued with a forward PE of 120 and a price‑to‑sales ratio of 53, far above the industry PE average of 24.9, and it carries a negative book value. Revenue has surged 167% year‑over‑year, but the company remains loss‑making with negative operating cash flow and a substantial debt load. The most material catalyst is the recent FDA warning letter and ensuing securities class‑action lawsuits, which triggered a 21% price plunge in March and have driven a flood of legal‑related investor alerts. These pressures, combined with decreasing volume and a support level near $6.80, suggest the near‑term outlook is fragile despite the long‑term potential of its immunotherapy pipeline.